Citius Oncology, Inc. (CTOR)vsViatris Inc (VTRS)
CTOR
Citius Oncology, Inc.
$0.58
-6.83%
HEALTHCARE · Cap: $56.77M
VTRS
Viatris Inc
$13.50
+1.05%
HEALTHCARE · Cap: $15.39B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 362464% more annual revenue ($14.30B vs $3.94M). CTOR leads profitability with a 0.0% profit margin vs -24.6%. VTRS earns a higher WallStSmart Score of 50/100 (C-).
CTOR
Avoid25
out of 100
Grade: F
VTRS
Buy50
out of 100
Grade: C-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -21.1% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : CTOR
The strongest argument for CTOR centers on Price/Book.
Bull Case : VTRS
The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.
Bear Case : CTOR
The primary concerns for CTOR are Revenue Growth, EPS Growth, Market Cap.
Bear Case : VTRS
The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
CTOR profiles as a value stock while VTRS is a turnaround play — different risk/reward profiles.
CTOR carries more volatility with a beta of 3.04 — expect wider price swings.
VTRS is growing revenue faster at 5.0% — sustainability is the question.
VTRS generates stronger free cash flow (551M), providing more financial flexibility.
Bottom Line
VTRS scores higher overall (50/100 vs 25/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Citius Oncology, Inc.
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Citius Oncology, Inc. is a clinical-stage biopharmaceutical firm committed to the development of groundbreaking cancer therapies tailored for underserved populations. The company boasts a promising pipeline that utilizes proprietary technologies to create innovative treatments aimed at various cancer indications, enhancing both efficacy and safety. Through strategic partnerships and a dedication to thorough clinical research, Citius Oncology is well-positioned for significant growth as it navigates crucial clinical trial phases and regulatory pathways, with the ultimate goal of improving patient outcomes in oncology.
Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?